Julio C. Chávez

Augusta University — United States

Medicine · Health Sciences

52h-index19.3kcitations608works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(319), CAR-T cell therapy research(290), Chronic Lymphocytic Leukemia Research(163), Viral-associated cancers and disorders(59), CNS Lymphoma Diagnosis and Treatment(50)

Publications607 total

Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
2025Open Access
Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
2025Open Access
Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
2025Open Access
Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
2025Open Access
Optimizing immunity to pneumococcus by vaccination with pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T cell immunotherapy
Blood·2025Open Access
Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study
Blood·2025
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results
Blood·2025Open Access
Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)
Blood·2025Open Access
Dynamic changes in the bone marrow niche following CD19-targeted CAR-T cell infusion in diffuse large B cell lymphoma (DLBCL).
Blood·2025Open Access
Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies
Blood·2025Open Access
Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update
Blood·2025
Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results
Blood·2025
Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas
Blood·2025Open Access
CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies
Blood·2025
Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma
Blood·2025Open Access
Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience
Blood·2025Open Access
Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma
Blood·2025Open Access
Real-world outcomes of Y90-ibritumomab tiuxetan (Zevalin) in low-grade B-cell non-Hodgkin lymphoma: A single-institution experience
Blood·2025
Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas
Expert Opinion on Biological Therapy·2025
Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas
Blood Neoplasia·2025Open Access
page 1 of 31Next →

Frequent Co-authors

Frederick L. Locke(14), Sattva S. Neelapu(12), Olalekan O. Oluwole(12), Brian T. Hill(12), Michael D. Jain(11), Javier Muñoz(10), Julie M. Vose(10), Lazaros J. Lekakis(8), Caron A. Jacobson(8), Patrick M. Reagan(8), Bijal Shah(8), David B. Miklos(7), Yi Lin(7), André Goy(7), Abhinav Deol(7), Armin Ghobadi(7), Joseph P. McGuirk(7), Alison R. Sehgal(7), Timothy S. Fenske(7), Nishitha Reddy(7)